NUVATION BIO INC (NUVB) Stock Price, Quote, News and Overview
NYSE:NUVB - New York Stock Exchange, Inc. - US67080N1019 - Common Stock - Currency: USD
NUVB Quote, Performance and Key Statistics
2.25
+0.22 (+10.84%)
The current stock price of NUVB is 2.25 USD. In the past month the price increased by 5.63%. In the past year, price decreased by -26.95%.
NUVB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.98 | 678.00B | ||
| JNJ | JOHNSON & JOHNSON | 15.19 | 367.19B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.48 | 302.61B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.54 | 222.20B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.8 | 216.87B | ||
| MRK | MERCK & CO. INC. | 9.99 | 195.88B | ||
| PFE | PFIZER INC | 7.18 | 130.67B | ||
| SNY | SANOFI-ADR | 13.71 | 128.55B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.41 | 95.71B | ||
| GSK | GSK PLC-SPON ADR | 7.06 | 78.75B | ||
| ZTS | ZOETIS INC | 26.91 | 72.25B | ||
| HLN | HALEON PLC-ADR | 22.57 | 49.87B |
Related stock screener links
About NUVB
Company Profile
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in San Francisco, California and currently employs 220 full-time employees. The company went IPO on 2020-07-01. The firm is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The firm is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. The company is conducting Phase I/II study of NUV-1511.
Company Info
NUVATION BIO INC
357 Tehama Street, Floor 3
San Francisco CALIFORNIA 94103 US
CEO: David Hung
Employees: 220
Phone: 14157543517
NUVATION BIO INC / NUVB FAQ
What is the stock price of NUVATION BIO INC today?
The current stock price of NUVB is 2.25 USD. The price increased by 10.84% in the last trading session.
What is the ticker symbol for NUVATION BIO INC stock?
The exchange symbol of NUVATION BIO INC is NUVB and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is NUVB stock listed?
NUVB stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for NUVATION BIO INC stock?
13 analysts have analysed NUVB and the average price target is 7.99 USD. This implies a price increase of 255.11% is expected in the next year compared to the current price of 2.25. Check the NUVATION BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NUVATION BIO INC worth?
NUVATION BIO INC (NUVB) has a market capitalization of 764.26M USD. This makes NUVB a Small Cap stock.
How many employees does NUVATION BIO INC have?
NUVATION BIO INC (NUVB) currently has 220 employees.
What are the support and resistance levels for NUVATION BIO INC (NUVB) stock?
NUVATION BIO INC (NUVB) has a support level at 2.2 and a resistance level at 2.32. Check the full technical report for a detailed analysis of NUVB support and resistance levels.
Is NUVATION BIO INC (NUVB) expected to grow?
The Revenue of NUVATION BIO INC (NUVB) is expected to grow by 594.71% in the next year. Check the estimates tab for more information on the NUVB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NUVATION BIO INC (NUVB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NUVB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NUVB, evaluating the profitability, health, valuation and growth aspects
- NUVATION BIO INC (NUVB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NUVATION BIO INC (NUVB) Sales and EPS estimates to see what analysts future expectations are.
- NUVATION BIO INC (NUVB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NUVATION BIO INC (NUVB) Insider and Institutional Ownership to learn about the owners and their transactions.
- NUVATION BIO INC (NUVB) Stock Chart to make your own analysis
- NUVATION BIO INC (NUVB) Latest news and press-releases to stay up to date.
Does NUVATION BIO INC (NUVB) stock pay dividends?
NUVB does not pay a dividend.
When does NUVATION BIO INC (NUVB) report earnings?
NUVATION BIO INC (NUVB) will report earnings on 2025-08-04, after the market close.
What is the Price/Earnings (PE) ratio of NUVATION BIO INC (NUVB)?
NUVATION BIO INC (NUVB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).
What is the Short Interest ratio of NUVATION BIO INC (NUVB) stock?
The outstanding short interest for NUVATION BIO INC (NUVB) is 13.37% of its float. Check the ownership tab for more information on the NUVB short interest.
NUVB Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to NUVB. When comparing the yearly performance of all stocks, NUVB is a bad performer in the overall market: 73.98% of all stocks are doing better.
NUVB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NUVB. While NUVB seems to be doing ok healthwise, there are quite some concerns on its profitability.
NUVB Financial Highlights
Over the last trailing twelve months NUVB reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS decreased by -96.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -123.13% | ||
| ROE | -144.56% | ||
| Debt/Equity | 0.01 |
NUVB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to NUVB. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -30.95% and a revenue growth 594.71% for NUVB